U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07581808) titled 'Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention' on May 05.
Brief Summary: This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.
Lowering low-density lipoprotein cholesterol (LDL-C) is essential to reduce the risk of cardiovascular events. While PCSK9 inhibitors are effective, many patients treated with a single agent do not reach recommended LDL-C targets, especially those who cannot take statins.
Inclisiran and alirocumab reduce LDL-C through di...